Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

Inclusion Criteria: * Males and non-pregnant, non-lactating females aged 18-65 * Weight ≥ 50.0 kg * BMI 18.0 - 40.0 kg/m2 * Able to participate, and willing to give written informed consent and to comply with the study restrictions * Subjects with hepatic impairment will have stable liver disease (Child Pugh A or Child Pugh B) Exclusion Criteria: * Pregnant or lactating women and male partners of women who are pregnant or lactating * Uncontrolled treated or untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg) * QTcF \> 450 msec for males and \> 470 msec for females at Screening or Day -1 * Donation or loss of blood over 350 mL within 60 days prior to screening * Any evidence of progressive liver disease within the last 4 weeks for subjects with hepatic impairment